Recent disclosures of clinical candidates: Highlights of the Society for Medicines Research Symposium held December 10th 2009 at the National Heart and Lung Institute, London, UK

Drugs of the Future

Volumn 35, Issue 4, 2010, Pages 349-358

  Coe, D ^a   Fox, D ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 [2 [5 CHLORO 2 (2,4 DIFLUOROBENZYLOXY)PHENYL] 1 CYCLOPENTENYL] 2 PYRIDINECARBOXYLIC ACID; AT 13387; GSK 180100B; GSK 269984A; GW 848687; HEAT SHOCK PROTEIN 90 INHIBITOR; METFORMIN PLUS SITAGLIPTIN; PF 2367982; PF 2413873; PF 489791; PROSTANOID RECEPTOR; RADICICOL; SITAGLIPTIN; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOMETRIOSIS; HUMAN; HYPOGLYCEMIA; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PAIN; PROTEIN STRUCTURE; PULMONARY HYPERTENSION;

EID: 77954576938     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2010.35.4.1487337     Document Type: Conference Paper

References (9)

1. Murray, C.W., Rees, D.C. The rise of fragment-based drug discovery. Nat Chem 2009, 1(3): 187-92.
2. Palmer, M. J., Bell, A.S., Fox, D.N.A., Brown, D.G. Design of second generation phosphodiesterase 5 inhibitors. Curr Top Med Chem 2007, 7(4): 405-19.
3. Lankas, G.R., Leiting, R., Roy, R.S. et al. Dipeptidyl peptidase IV Inhibition for the treatment of type 2 diabetes: Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005, 54(10): 2988-94.
4. Caldwell, C.G., Chen, P., He, J. et al. Fluoropyrimidine amides as dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2004, 14(5): 1265-8.
5. Hansen, K.B., Hsiao, Y., Xu, F. et al. Highly efficient asymmetric synthesis of sitagliptin. J Am Chem Soc 2009, 131(25): 8798-804.
6. Wolf, J.P., Hsiu, J.G., Anderson, T.L., Ulmann, A., Baulieu, E.E., Hodgen, G.D. Noncompetitive antiestrogenic effect of RU 486 in blocking the estrogen-stimulated luteinizing hormone surge and the proliferative action of estradiol on endometrium in castrate monkeys. Fertil Steril 1989, 52(6): 1055-60.
7. Leeson, P.D., Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 2007, 6(11): 881-90.
8. Hall, A., Billinton, A., Giblin, G.M.P. EP7 antagonists for the treatment of inflammatory pain. Curr Opin Drug Discov Devel 2007,10(5): 597-612.
9. Giblin, G.M.P., Bit, R.A., Brown, S.H. et al. The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl-2- pyridinecarboxylic acid, CW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of Inflammatory pain. Bioorg Med Chem Lett 2007, 17(2): 385-9.